钠-葡萄糖共转运蛋白-2抑制剂能改善心力衰竭患者的睡眠质量、焦虑和生活质量吗?

IF 2.3 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Ilke Erbay, Naile Eris Gudul, Ahmet Furkan Suner, Pelin Aladag, Umit Karacar, Ahmet Avci
{"title":"钠-葡萄糖共转运蛋白-2抑制剂能改善心力衰竭患者的睡眠质量、焦虑和生活质量吗?","authors":"Ilke Erbay,&nbsp;Naile Eris Gudul,&nbsp;Ahmet Furkan Suner,&nbsp;Pelin Aladag,&nbsp;Umit Karacar,&nbsp;Ahmet Avci","doi":"10.1002/clc.70190","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure (HF), but their effect on sleep quality (SQ) and patient-centered outcomes remains unclear.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study aims to evaluate the impact of SGLT2 inhibitor use on SQ, anxiety, and quality of life in patients with HF.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This longitudinal observational study included 95 HF patients grouped by SGLT2 inhibitor use. A total of 79 patients (SGLT2 inhibitor group: 33; non-SGLT2 inhibitor group: 46) completed a 6-month follow-up. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), anxiety with the Beck Anxiety Inventory (BAI), and quality of life with the Short Form-36 (SF-36). Subgroup analyses were conducted based on left ventricular ejection fraction (LVEF), and logistic regression was used to identify predictors of PSQI improvement.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>At baseline, PSQI scores were slightly better in the SGLT2 inhibitor group (<i>p</i> = 0.036), while BAI and SF-36 scores were similar. At follow-up, the SGLT2 inhibitor group showed significant improvements in PSQI (<i>p</i> &lt; 0.001) and BAI (<i>p</i> = 0.002), whereas no significant changes were observed in the non-SGLT2 inhibitor group for either PSQI (<i>p</i> = 0.698) or BAI (<i>p</i> = 0.373). PSQI improvement was observed in SGLT2 users regardless of LVEF. In multivariate analysis, SGLT2 inhibitor use was an independent predictor of PSQI improvement (adjusted OR: 4.255; <i>p</i> = 0.010).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>SGLT2 inhibitor use was associated with improved SQ and reduced anxiety in patients with HF, suggesting symptom-related benefits beyond cardiovascular effects.</p>\n </section>\n </div>","PeriodicalId":10201,"journal":{"name":"Clinical Cardiology","volume":"48 8","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.70190","citationCount":"0","resultStr":"{\"title\":\"Can Sodium-Glucose Co-Transporter-2 Inhibitors Improve Sleep Quality, Anxiety, and Quality of Life in Patients With Heart Failure?\",\"authors\":\"Ilke Erbay,&nbsp;Naile Eris Gudul,&nbsp;Ahmet Furkan Suner,&nbsp;Pelin Aladag,&nbsp;Umit Karacar,&nbsp;Ahmet Avci\",\"doi\":\"10.1002/clc.70190\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure (HF), but their effect on sleep quality (SQ) and patient-centered outcomes remains unclear.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>This study aims to evaluate the impact of SGLT2 inhibitor use on SQ, anxiety, and quality of life in patients with HF.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This longitudinal observational study included 95 HF patients grouped by SGLT2 inhibitor use. A total of 79 patients (SGLT2 inhibitor group: 33; non-SGLT2 inhibitor group: 46) completed a 6-month follow-up. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), anxiety with the Beck Anxiety Inventory (BAI), and quality of life with the Short Form-36 (SF-36). Subgroup analyses were conducted based on left ventricular ejection fraction (LVEF), and logistic regression was used to identify predictors of PSQI improvement.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>At baseline, PSQI scores were slightly better in the SGLT2 inhibitor group (<i>p</i> = 0.036), while BAI and SF-36 scores were similar. At follow-up, the SGLT2 inhibitor group showed significant improvements in PSQI (<i>p</i> &lt; 0.001) and BAI (<i>p</i> = 0.002), whereas no significant changes were observed in the non-SGLT2 inhibitor group for either PSQI (<i>p</i> = 0.698) or BAI (<i>p</i> = 0.373). PSQI improvement was observed in SGLT2 users regardless of LVEF. In multivariate analysis, SGLT2 inhibitor use was an independent predictor of PSQI improvement (adjusted OR: 4.255; <i>p</i> = 0.010).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>SGLT2 inhibitor use was associated with improved SQ and reduced anxiety in patients with HF, suggesting symptom-related benefits beyond cardiovascular effects.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10201,\"journal\":{\"name\":\"Clinical Cardiology\",\"volume\":\"48 8\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.70190\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/clc.70190\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cardiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.70190","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

钠-葡萄糖共转运蛋白-2 (SGLT2)抑制剂可改善心力衰竭(HF)患者的心血管结局,但其对睡眠质量(SQ)和以患者为中心的结局的影响尚不清楚。目的本研究旨在评估使用SGLT2抑制剂对心衰患者SQ、焦虑和生活质量的影响。方法对95例HF患者进行纵向观察研究,按SGLT2抑制剂使用情况分组。79例患者(SGLT2抑制剂组33例;非sglt2抑制剂组:46例)完成了6个月的随访。使用匹兹堡睡眠质量指数(PSQI)评估睡眠质量,使用贝克焦虑量表(BAI)评估焦虑,使用SF-36评估生活质量。根据左室射血分数(LVEF)进行亚组分析,并采用logistic回归确定PSQI改善的预测因素。结果在基线时,SGLT2抑制剂组PSQI评分略好(p = 0.036),而BAI和SF-36评分相似。在随访中,SGLT2抑制剂组PSQI (p < 0.001)和BAI (p = 0.002)均有显著改善,而非SGLT2抑制剂组PSQI (p = 0.698)和BAI (p = 0.373)均无显著变化。无论LVEF如何,SGLT2患者PSQI均有改善。在多变量分析中,SGLT2抑制剂的使用是PSQI改善的独立预测因子(调整OR: 4.255;p = 0.010)。结论:使用SGLT2抑制剂与心衰患者SQ改善和焦虑减少相关,提示症状相关的益处超出心血管效应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Can Sodium-Glucose Co-Transporter-2 Inhibitors Improve Sleep Quality, Anxiety, and Quality of Life in Patients With Heart Failure?

Can Sodium-Glucose Co-Transporter-2 Inhibitors Improve Sleep Quality, Anxiety, and Quality of Life in Patients With Heart Failure?

Background

Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure (HF), but their effect on sleep quality (SQ) and patient-centered outcomes remains unclear.

Objective

This study aims to evaluate the impact of SGLT2 inhibitor use on SQ, anxiety, and quality of life in patients with HF.

Methods

This longitudinal observational study included 95 HF patients grouped by SGLT2 inhibitor use. A total of 79 patients (SGLT2 inhibitor group: 33; non-SGLT2 inhibitor group: 46) completed a 6-month follow-up. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), anxiety with the Beck Anxiety Inventory (BAI), and quality of life with the Short Form-36 (SF-36). Subgroup analyses were conducted based on left ventricular ejection fraction (LVEF), and logistic regression was used to identify predictors of PSQI improvement.

Results

At baseline, PSQI scores were slightly better in the SGLT2 inhibitor group (p = 0.036), while BAI and SF-36 scores were similar. At follow-up, the SGLT2 inhibitor group showed significant improvements in PSQI (p < 0.001) and BAI (p = 0.002), whereas no significant changes were observed in the non-SGLT2 inhibitor group for either PSQI (p = 0.698) or BAI (p = 0.373). PSQI improvement was observed in SGLT2 users regardless of LVEF. In multivariate analysis, SGLT2 inhibitor use was an independent predictor of PSQI improvement (adjusted OR: 4.255; p = 0.010).

Conclusion

SGLT2 inhibitor use was associated with improved SQ and reduced anxiety in patients with HF, suggesting symptom-related benefits beyond cardiovascular effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Cardiology
Clinical Cardiology 医学-心血管系统
CiteScore
5.10
自引率
3.70%
发文量
189
审稿时长
4-8 weeks
期刊介绍: Clinical Cardiology provides a fully Gold Open Access forum for the publication of original clinical research, as well as brief reviews of diagnostic and therapeutic issues in cardiovascular medicine and cardiovascular surgery. The journal includes Clinical Investigations, Reviews, free standing editorials and commentaries, and bonus online-only content. The journal also publishes supplements, Expert Panel Discussions, sponsored clinical Reviews, Trial Designs, and Quality and Outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信